Targeting HIF-2α and anemia: A therapeutic breakthrough for clear-cell renal cell carcinoma

Autor: Rioja, Patricia, Rey-Cardenas, M., De Velasco, Guillermo

Publikováno v: In Cancer Treatment Reviews September 2024 129

Response and Outcomes of Maintenance Avelumab After Platinum-Based Chemotherapy (PBC) in Patients With Advanced Urothelial Carcinoma (aUC): "Real World" Experience.

Autor: Bakaloudi DR; Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA., Talukder R; Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA., Lin GI; Department of Epidemiology, University of Washington, Seattle, WA., Makrakis D; Department of Medicine, Jacobi Medical Center-Albert Einstein College of Medicine, Bronx, NY., Diamantopoulos LN; Department of Medicine, University of Pittsburgh, Pittsburgh, PA., Tripathi N; Division of Oncology, Department of Medicine, University of Utah, Salt Lake City, UT., Agarwal N; Division of Oncology, Department of Medicine, University of Utah, Salt Lake City, UT., Zakopoulou R; 2nd Propaedeutic Department of Internal Medicine, ATTIKON University Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece., Bamias A; 2nd Propaedeutic Department of Internal Medicine, ATTIKON University Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece., Brown JR; Division of Oncology, University Hospitals Seidman Cancer Center, Clevelant, OH., Pinato DJ; Department of Surgery and Cancer, Imperial College London, Hammersmith Campus, London, UK; Division of Oncology, Department of Translational Medicine (DIMET), University of Piemonte Orientale, Novara, Italy., Korolewicz J; Department of Surgery and Cancer, Imperial College London, Hammersmith Campus, London, UK., Jindal T; Division of Hematology/Oncology, Department of Medicine, Helen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA., Koshkin VS; Division of Hematology/Oncology, Department of Medicine, Helen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA., Murgić J; Department of Oncology and Nuclear Medicine, University Hospital Center Sestre Milosrdnice, School of Dental Medicine, Zagreb, Croatia., Miletić M; Department of Oncology and Nuclear Medicine, University Hospital Center Sestre Milosrdnice, School of Dental Medicine, Zagreb, Croatia., Frobe A; Department of Oncology and Nuclear Medicine, Faculty of Dentistry, University Hospital Center Sestre Milosrdnice, Zagreb, Croatia., Johnson J; Division of Oncology, Department of Medicine, University of Iowa, Iowa City, IA., Zakharia Y; Division of Oncology, Department of Medicine, University of Iowa, Iowa City, IA., Drakaki A; Division of Hematology/Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA., Rodriguez-Vida A; Medical Oncology Department, Hospital del Mar, IMM Research Institute, Barcelona, Spain., Rey-Cárdenas M; Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain., Castellano D; Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain., Buznego LA; Department of Oncology, University Hospital Marqués of Valdecilla, IDIVAL Santander, Cantabria, Spain., Duran I; Department of Oncology, University Hospital Marqués of Valdecilla, IDIVAL Santander, Cantabria, Spain., Carballeira CC; Department of Oncology, University Hospital Marqués of Valdecilla, IDIVAL Santander, Cantabria, Spain., Barrera RM; Department of Medical Oncology, Vall d'Hebron Institute of Oncology, Vall d' Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain., Marmorejo D; Department of Medical Oncology, Vall d'Hebron Institute of Oncology, Vall d' Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain., McKay RR; Moores Cancer Center, University of California San Diego, La Jolla, CA., Stewart T; Moores Cancer Center, University of California San Diego, La Jolla, CA., Gupta S; Department of Hematology and Oncology, Taussig cancer Institute, Cleveland Clinic Foundation, Cleveland, OH., Ruplin AT; Department of Pharmacy, Fred Hutchinson Cancer Center, Seattle, WA., Yu EY; Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA., Khaki AR; Division of Oncology, Department of Medicine, Stanford University, Palo Alto, CA. Electronic address: alikhaki@stanford.edu., Grivas P; Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA. Electronic address: pgrivas@uw.edu.

Publikováno v: Clinical genitourinary cancer [Clin Genitourin Cancer] 2023 Oct; Vol. 21 (5), pp. 584-593. Date of Electronic Publication: 2023 Jun 20.

Digging into phenotype change in mismatch repair deficient endometrial carcinoma and treatment with immune checkpoint inhibition, a case report.

Autor: Rey-Cárdenas M; Medical Oncology Department, 12 de Octubre University Hospital, Madrid, Spain., Parrilla-Rubio L; Pathology Department, 12 de Octubre University Hospital, Madrid, Spain., Manso L; Medical Oncology Department, 12 de Octubre University Hospital, Madrid, Spain., Sanchez-Bayona R; Medical Oncology Department, 12 de Octubre University Hospital, Madrid, Spain., Alvarez-Conejo C; Gynecology Department, 12 de Octubre University Hospital, Madrid, Spain., Madariaga A; Medical Oncology Department, 12 de Octubre University Hospital, Madrid, Spain.

Publikováno v: Gynecologic oncology reports [Gynecol Oncol Rep] 2023 Sep 25; Vol. 49, pp. 101278. Date of Electronic Publication: 2023 Sep 25 (Print Publication: 2023).

1768P Clinical outcomes with platinum-based chemotherapy after progression on frontline immunotherapy in metastatic urothelial cancer (mUC)

Autor: Szabados, B.E., Stockem, C.F., Castellano Gauna, D.E., Gomez de Liano Lista, A., Rey Cardenas, M., Perez Valderrama, B., Powles, T.B., van der Heijden, M.S.

Publikováno v: In Annals of Oncology September 2022 33 Supplement 7:S1346-S1346

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.